NCT05571839 2026-03-13A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid TumorsSeagen Inc.Phase 1 Active not recruiting41 enrolled
NCT05451849 2025-08-27A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing CancerTCR2 TherapeuticsPhase 1/2 Active not recruiting6 enrolled
NCT05215574 2024-10-10Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid TumorsNGM Biopharmaceuticals, IncPhase 1 Active not recruiting130 enrolled
NCT05311618 2024-04-01Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid TumorsNGM Biopharmaceuticals, IncPhase 1 Active not recruiting71 enrolled